Business
Med BioGene Inc.'s Chief Scientific Officer to present at prestigous P.O.E.T.I.C. Conference to be held July 19-21 in Banff, Alberta
Med BioGene Inc.'s Chief Scientific Officer to present at prestigous P.O.E.T.I.C. Conference to be held July 19-21 in Banff, Alberta.
About this update from Many Bright Ideas Technologies Inc
[{"type":"text","content":"\n\n\n\n\nVANCOUVER, July 11 /CNW/ - Med BioGene Inc. (TSX Venture: MBI) is pleased\nto announce that its Chief Scientific Officer, Dr. Nathan Yoganathan, will be\npresenting at the Pediatric Oncology Experimental Therapeutics Investigation\nConsortium, or P.O.E.T.I.C., Conference being held July 19-21 in Banff,\nAlberta. The conference is being hosted by the Tom Baker Cancer Centre, one of\ntwo major cancer centres in Alberta dedicated to patient care and treatment,\nresearch and teaching. Dr. Yoganathan will be presenting on molecular\ndiagnostics and MBI's Hematological Cancer Profiling System as a new tool for\nrapid diagnosis and prognosis of hematological cancer.\n\"Med BioGene is very pleased that Dr. Yoganathan has been asked to speak\nat such a prestigious event. POETIC is composed of an elite group of research\nhospitals and includes such prestigious institutions as Johns Hopkins and\nSloan Kettering, two of the most esteemed cancer hospitals in the USA. The\ngroup is internationally renowned for its work in Phase One Clinical Trials -\nthe most leading edge drug trial work in medicine,\" stated Erinn Broshko,\nChief Executive Officer of MBI.\n\nAbout Med BioGene\n\nMBI is a biotechnology company with advanced research expertise in gene\nexpression technology. MBI's mission is to become the market leader in the\nsupply of content for molecular-based diagnostic micro arrays. MBI intends to\nfulfill this mission by developing and marketing genetic content for\nmolecular-based human diagnostic tests. Molecular diagnostics, based on\ngenetic expression, is a developing technology field that has the potential to\nreplace certain of today's standard diagnostic tests. MBI intends to utilize\nits expertise in gene expression, bioinformatics and micro arrays to develop\nthe diagnostic tests' genetic content. From the tens of thousands of genes in\nthe human genome, MBI is identifying those genes, known as \"bio markers,\"\nwhich mark the presence of various disease conditions.\nMBI's initial focus will be developing diagnostic tests for certain types\nof cancer, specifically lymphoma and leukemia. In the future, MBI intends to\ndevelop diagnostic tests to identify the earliest stages of heart disease or\nthe presence of an infectious disease. These diagnostic test kits will be\ndesigned to provide additional information to phys...